12:00 PM EDT, 03/31/2025 (MT Newswires) -- Genmab ( GMAB ) said Monday that the European Commission has granted marketing authorization for Tivdak as a treatment for adult patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy.

The company said the approval was based on data from a phase 3 trial that met its primary endpoint of overall survival, with Tivdak demonstrating a 30% reduction in risk of death compared with chemotherapy.

Tivdak, also known as tisotumab vedotin, is co-developed and co-commercialized by Genmab ( GMAB ) and Pfizer ( PFE ) globally, with Pfizer ( PFE ) holding its marketing authorization in the European Union until its transfer to Genmab ( GMAB ) within the year, according to the statement.

Price: 19.56, Change: -0.34, Percent Change: -1.73